Barry N Falgout
age ~68
from Silver Spring, MD
- Also known as:
-
- Barry Neil Falgout
- Barry Neil Small
- Phone and address:
- 15006 Eardley Ct, Silver Spring, MD 20906
Barry Falgout Phones & Addresses
- 15006 Eardley Ct, Silver Spring, MD 20906
- 14000 Cove Ln, Rockville, MD 20851 • 3013400661
- 14000 Cove Ln APT 103, Rockville, MD 20851 • 3013400661
- 4929 Waterfowl Way, Rockville, MD 20853 • 3019241355
- 7804 Marioak Dr, Elkridge, MD 21075
- Catonsville, MD
Us Patents
-
Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3′-Utr Of Dengue Types 1, 2, 3, And 4 Or Antigenic Chimeric Dengue Viruses 1, 2, 3, And 4
view source -
US Patent:8075903, Dec 13, 2011
-
Filed:Mar 4, 2009
-
Appl. No.:12/398043
-
Inventors:Stephen S. Whitehead - Montgomery Village MD, US
Brian R. Murphy - Bethesda MD, US
Lewis Markoff - Bethesda MD, US
Barry Falgout - Rockville MD, US
Joseph Blaney - Frederick MD, US
Kathryn Hanley - Las Cruces NM, US -
Assignee:The United States of America as represented by the Department of Health and Human Services - Washington DC
-
International Classification:A61K 39/295
-
US Classification:4242021, 4242181, 4241991, 4242051, 4353201, 4352351, 435236
-
Abstract:The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
-
Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-Utr Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4
view source -
US Patent:20070009552, Jan 11, 2007
-
Filed:Oct 21, 2004
-
Appl. No.:10/970640
-
Inventors:Stephen Whitehead - Montgomery Village MD, US
Brian Murphy - Bethesda MD, US
Lewis Markoff - Bethesda MD, US
Barry Falgout - Rockville MD, US
Joseph Blaney - Frederick MD, US
Kathryn Hanley - Las Cruces NM, US -
International Classification:A61K 39/12
C12N 15/86 -
US Classification:424218100, 435456000
-
Abstract:The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
-
Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-Utr Of Dengue Types 1, 2, 3, And 4, Or Antigenic Chimeric Dengue Viruses 1, 2, 3, And 4
view source -
US Patent:20130011433, Jan 10, 2013
-
Filed:Nov 28, 2011
-
Appl. No.:13/305639
-
Inventors:Stephen S. Whitehead - Bethesda MD, US
Brian R. Murphy - Bethesda MD, US
Lewis Markoff - Bethesda MD, US
Barry Falgout - Rockville MD, US
Joseph Blaney - Gettysburg PA, US
Kathryn Hanley - Las Cruces NM, US -
Assignee:The Government of the USA, as represented by the Secretary, Department of Health and Human Services - Bethesda MD
-
International Classification:A61K 39/295
C07H 21/00
C12N 15/62
A61P 31/14
A61P 37/04 -
US Classification:4242021, 536 234, 536 243
-
Abstract:The invention relates to a dengue virus tetravalent vaccine containing a common nucleotide deletion (Δ) in the ′-untranslated region of the genome of dengue virus serotypes , and , or antigenic chimeric dengue viruses of serotypes , and
-
Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-Utr Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4
view source -
US Patent:20200392469, Dec 17, 2020
-
Filed:Sep 1, 2020
-
Appl. No.:17/009448
-
Inventors:- Bethesda MD, US
Brian R. Murphy - Bethesda MD, US
Lewis Markoff - Bethesda MD, US
Barry Falgout - Rockville MD, US
Joseph Blaney - Gettysburg PA, US
Kathryn Hanley - Las Cruces NM, US -
Assignee:The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD
-
International Classification:C12N 7/00
A61K 39/12 -
Abstract:The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
-
Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-Utr Of Dengue Types 1, 2, 3, And 4, Or Antigenic Chimeric Dengue Viruses 1, 2, 3, And 4
view source -
US Patent:20180010099, Jan 11, 2018
-
Filed:Sep 20, 2017
-
Appl. No.:15/710672
-
Inventors:- Bethesda MD, US
Brian R. Murphy - Bethesda MD, US
Lewis Markoff - Bethesda MD, US
Barry Falgout - Rockville MD, US
Joseph Blaney - Gettysburg PA, US
Kathryn Hanley - Las Cruces NM, US -
Assignee:The United States of America,as represented by the Secretary, Department of Helath and Human Service - Bethesda MD
-
International Classification:C12N 7/00
A61K 39/12
A61K 39/00 -
Abstract:The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
Classmates
Barry Falgout
view sourceSchools:
Woodlawn High School Braithwaite LA 1961-1965
Community:
Frank Oddo, Lucien Cusimano, Lucille Williams, Mary Pizzettier, Carol Cusimano
Barry Falgout
view sourceSchools:
Woodland High School Braithwaite LA 1961-1965
Community:
Glenn Laurie, Mary Daigle, Bonnie Hingle, Beeverly Picarella
Youtube
Get Report for Barry N Falgout from Silver Spring, MD, age ~68